Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Bilayer Therapeutics Logo
Bilayer Therapeutics Growth Score
63
CB Rank
99516
Heat Score
51
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.
Founded
obfuscation
PrivateSeed Cambridge, Massachusetts, United States1-10 bilayer-therapeutics.com/
Biotechnology
Health Care
Life Science
Therapeutics
Overview

Bilayer Therapeutics
Total Funding
obfuscation
Growth Score
63
Heat Score
51

Total Funding
obfuscation
Seed raised
obfuscation
Growth Score63
-2 pts
in past quarter
Heat Score 51
-3 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Bilayer Therapeutics

CB Rank
99516
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.
Founded
obfuscation
PrivateSeed Cambridge, Massachusetts, United States1-10 bilayer-therapeutics.com/
Biotechnology
Health Care
Life Science
Therapeutics

Funding Rounds

Seed
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Key People

  • Photo of Thomas A. Collet
    Thomas A. Collet: President & CEO
    Past Role: Meditrina Pharmaceuticals, President and Chief Executive Officer

Details

Legal Name Bilayer Therapeutics, Inc.
Operating Status Active
Company Type For Profit
About the Company
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
Phone Number 734-358-9015
Contact Email tacollet@alum.mit.edu
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Bilayer Tablet Technology
A proprietary delivery system designed for the lower gastrointestinal tract, featuring a dual mode of action with an immediate release layer and an extended-release therapeutic layer.
Metabolic and Motility Disorder Treatments
Treatments targeting metabolic syndrome and motility disorders using chenodeoxycholate (CDC) to activate GLP-1 and other incretins, and to improve fluid influx and peristalsis in the colon.

Research & Development

Bilayer Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed
obfuscation
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
1
obfuscation
— Seed

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Diamond Biofund Inc. Logo
Diamond Biofund Inc.
—
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
—
Diamond Biofund Inc. Logo
Diamond Biofund Inc.
—
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
—
Diamond Biofund Inc. Logo
Diamond Biofund Inc.
—
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
—
Diamond Biofund Inc. Logo
Diamond Biofund Inc.
—
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
—
Diamond Biofund Inc. Logo
Diamond Biofund Inc.
—
Seed Round - Bilayer Therapeutics Logo
Seed Round - Bilayer Therapeutics
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 1

Employee Profiles

News

News and Press

News•Mar 28, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

260

IT Spend

$171KThis year, Bilayer Therapeutics is projected to spend $171K on IT, according to Aberdeen.

Active Website Tech Count

8Bilayer Therapeutics is actively using 8 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and  Mobile Non Scaleable Content.

Total IP

1Bilayer Therapeutics has 1 registered patent in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Bilayer Therapeutics's headquarters? Bilayer Therapeutics is located in Cambridge, Massachusetts, United States.Who invested in Bilayer Therapeutics? Bilayer Therapeutics has 2 investors including Diamond Biofund Inc. and  Kendall Capital Partners.When was the last funding round for Bilayer Therapeutics? Bilayer Therapeutics closed its last funding round on
obfuscation
from a Seed round.Who are Bilayer Therapeutics's competitors? Alternatives and possible competitors to Bilayer Therapeutics may include AbbVie, Pfizer, and  Takeda.How much funding has Bilayer Therapeutics raised to date? Bilayer Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(6852caf 1)
|